{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T20:02:56Z","timestamp":1792699376706,"version":"4.5.0"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,11,19]],"date-time":"2024-11-19T00:00:00Z","timestamp":1731974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-024-79537-2","type":"journal-article","created":{"date-parts":[[2024,11,18]],"date-time":"2024-11-18T21:02:20Z","timestamp":1731963740000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Selinexor combined with bortezomib, lenalidomide, and dexamethasone for the treatment of newly diagnosed multiple myeloma with extramedullary disease"],"prefix":"10.1038","volume":"14","author":[{"given":"Junjing","family":"Yin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglu","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxia","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lumei","family":"Hao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongying","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuping","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,19]]},"reference":[{"key":"79537_CR1","doi-asserted-by":"publisher","first-page":"e538","DOI":"10.1016\/s1470-2045(14)70442-5","volume":"15","author":"SV Rajkumar","year":"2014","unstructured":"Rajkumar, S. V. et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 15, e538\u2013548. https:\/\/doi.org\/10.1016\/s1470-2045(14)70442-5 (2014).","journal-title":"Lancet Oncol."},{"key":"79537_CR2","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.blre.2019.04.002","volume":"36","author":"S Sevcikova","year":"2019","unstructured":"Sevcikova, S. et al. Extramedullary disease in multiple myeloma - controversies and future directions. Blood Rev. 36, 32\u201339. https:\/\/doi.org\/10.1016\/j.blre.2019.04.002 (2019).","journal-title":"Blood Rev."},{"key":"79537_CR3","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/bjh.17338","volume":"194","author":"L Rosi\u00f1ol","year":"2021","unstructured":"Rosi\u00f1ol, L. et al. Expert review on soft-tissue plasmacytomas in multiple myeloma: definition, disease assessment and treatment considerations. Br. J. Haematol. 194, 496\u2013507. https:\/\/doi.org\/10.1111\/bjh.17338 (2021).","journal-title":"Br. J. Haematol."},{"key":"79537_CR4","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1182\/blood-2019-129038","volume":"134","author":"AJ Yee","year":"2019","unstructured":"Yee, A. J. et al. Response to Therapy and the effectiveness of treatment with selinexor and dexamethasone in patients with Penta-exposed triple-class Refractory Myeloma who had plasmacytomas. Blood. 134, 5. https:\/\/doi.org\/10.1182\/blood-2019-129038 (2019).","journal-title":"Blood"},{"key":"79537_CR5","doi-asserted-by":"publisher","first-page":"e328","DOI":"10.1016\/s1470-2045(16)30206-6","volume":"17","author":"S Kumar","year":"2016","unstructured":"Kumar, S. et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. Lancet Oncol. 17, e328\u2013e346. https:\/\/doi.org\/10.1016\/s1470-2045(16)30206-6 (2016).","journal-title":"Lancet Oncol."},{"key":"79537_CR6","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1016\/j.ad.2019.05.009","volume":"112","author":"A Freites-Martinez","year":"2021","unstructured":"Freites-Martinez, A., Santana, N., Arias-Santiago, S. & Viera, A. Using the common terminology criteria for adverse events (CTCAE - version 5.0) to evaluate the severity of adverse events of Anticancer therapies. Actas Dermosifiliogr (Engl Ed). 112, 90\u201392. https:\/\/doi.org\/10.1016\/j.ad.2019.05.009 (2021).","journal-title":"Actas Dermosifiliogr (Engl Ed)"},{"key":"79537_CR7","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/ajh.24451","volume":"91","author":"F Jardin","year":"2016","unstructured":"Jardin, F. et al. Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. Am. J. Hematol. 91, 923\u2013930. https:\/\/doi.org\/10.1002\/ajh.24451 (2016).","journal-title":"Am. J. Hematol."},{"key":"79537_CR8","doi-asserted-by":"publisher","first-page":"2357","DOI":"10.1038\/leu.2013.172","volume":"27","author":"J Schmidt","year":"2013","unstructured":"Schmidt, J. et al. Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276. Leukemia. 27, 2357\u20132365. https:\/\/doi.org\/10.1038\/leu.2013.172 (2013).","journal-title":"Leukemia"},{"key":"79537_CR9","doi-asserted-by":"publisher","first-page":"100758","DOI":"10.1016\/j.blre.2020.100758","volume":"46","author":"K Benkova","year":"2021","unstructured":"Benkova, K., Mihalyova, J., Hajek, R. & Jelinek, T. Selinexor, selective inhibitor of nuclear export: unselective bullet for blood cancers. Blood Rev. 46, 100758. https:\/\/doi.org\/10.1016\/j.blre.2020.100758 (2021).","journal-title":"Blood Rev."},{"key":"79537_CR10","doi-asserted-by":"publisher","first-page":"2875","DOI":"10.1038\/s41375-020-0958-y","volume":"34","author":"B Nachmias","year":"2020","unstructured":"Nachmias, B. & Schimmer, A. D. Targeting nuclear import and export in hematological malignancies. Leukemia. 34, 2875\u20132886. https:\/\/doi.org\/10.1038\/s41375-020-0958-y (2020).","journal-title":"Leukemia"},{"key":"79537_CR11","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13045-016-0304-z","volume":"9","author":"JG Turner","year":"2016","unstructured":"Turner, J. G. et al. Treatment of acquired drug resistance in multiple myeloma by combination therapy with XPO1 and topoisomerase II inhibitors. J. Hematol. Oncol. 9, 73. https:\/\/doi.org\/10.1186\/s13045-016-0304-z (2016).","journal-title":"J. Hematol. Oncol."},{"key":"79537_CR12","doi-asserted-by":"publisher","first-page":"78883","DOI":"10.18632\/oncotarget.12428","volume":"7","author":"T Kashyap","year":"2016","unstructured":"Kashyap, T. et al. Selinexor, a selective inhibitor of Nuclear Export (SINE) compound, acts through NF-\u03baB deactivation and combines with proteasome inhibitors to synergistically induce tumor cell death. Oncotarget. 7, 78883\u201378895. https:\/\/doi.org\/10.18632\/oncotarget.12428 (2016).","journal-title":"Oncotarget"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79537-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79537-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79537-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T03:28:58Z","timestamp":1732246138000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-024-79537-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,19]]},"references-count":12,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["79537"],"URL":"https:\/\/doi.org\/10.1038\/s41598-024-79537-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-4702232\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,19]]},"assertion":[{"value":"8 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and was approved by the independent ethics committee of Qingdao Municipal Hospital (No. 2022Y042).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}},{"value":"All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Patient consent"}},{"value":"ChiCTR2200062860.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial registration"}},{"value":"The authors declare no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The authors declare no conflict of interest.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"28557"}}